Abstract | Purpose: Methods: We compared the in vitro activity of IDB0062 and conventional drugs using cell proliferation, wound healing, and Transwell assays. The in vivo efficacy of IDB0062 was determined using mouse choroidal neovascularization and oxygen-induced retinopathy models. To evaluate the ocular distribution of IDB0062, we intravitreally administered IDB0062 and ranibizumab to cynomolgus monkeys and measured the retinal drug levels. Results: Conclusions: Through neuropilin 1 binding, IDB0062 can improve the efficacy and accelerate the onset of pharmacological action in the posterior segment, which is targeted for macular degeneration, thereby improving drug responsiveness in drug-resistant patients. Translational Relevance:
|
Authors | Seongbeom Kim, Gihong Min, Bomin Kim, Doseop Lee, Myongjae Lee, Jong-Hee Ko, Hyuk-Sang Kwon |
Journal | Translational vision science & technology
(Transl Vis Sci Technol)
Vol. 10
Issue 14
Pg. 35
(12 01 2021)
ISSN: 2164-2591 [Electronic] United States |
PMID | 34967833
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Immunoglobulin Fragments
- Pharmaceutical Preparations
- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor B
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Humans
- Immunoglobulin Fragments
(therapeutic use)
- Intravitreal Injections
- Macular Degeneration
(drug therapy)
- Mice
- Pharmaceutical Preparations
- Vascular Endothelial Growth Factor A
(therapeutic use)
- Vascular Endothelial Growth Factor B
(therapeutic use)
|